Azenta, Inc. AZTA
We take great care to ensure that the data presented and summarized in this overview for Azenta, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AZTA
View all-
Black Rock Inc. New York, NY4.81MShares$127 Million0.01% of portfolio
-
Politan Capital Management LP New York, NY4.61MShares$121 Million14.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$119 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.03MShares$79.9 Million0.04% of portfolio
-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA2.24MShares$58.9 Million0.27% of portfolio
-
Conestoga Capital Advisors, LLC1.92MShares$50.5 Million1.0% of portfolio
-
State Street Corp Boston, MA1.76MShares$46.3 Million0.0% of portfolio
-
Schroder Investment Management Group London, X01.41MShares$37 Million0.07% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.3MShares$34.2 Million0.55% of portfolio
-
Macquarie Group LTD Australia, C31.06MShares$27.8 Million0.06% of portfolio
Latest Institutional Activity in AZTA
Top Purchases
Top Sells
About AZTA
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Insider Transactions at AZTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Feb 11
2025
|
Lawrence Y. Lin EVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
2,200
+5.54%
|
$101,200
$46.0 P/Share
|
|
Feb 07
2025
|
Quentin Koffey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,040
+44.52%
|
-
|
|
Feb 07
2025
|
Erica Mc Laughlin |
BUY
Grant, award, or other acquisition
|
Direct |
4,040
+19.33%
|
$210,080
$52.32 P/Share
|
|
Feb 07
2025
|
Dipal Doshi |
BUY
Grant, award, or other acquisition
|
Direct |
4,040
+50.0%
|
$210,080
$52.32 P/Share
|
|
Feb 07
2025
|
Tina Susan Nova |
BUY
Grant, award, or other acquisition
|
Direct |
4,040
+28.55%
|
$210,080
$52.32 P/Share
|
|
Feb 07
2025
|
Robyn C Davis |
BUY
Grant, award, or other acquisition
|
Direct |
4,040
+10.73%
|
$210,080
$52.32 P/Share
|
|
Feb 07
2025
|
Frank Casal |
BUY
Grant, award, or other acquisition
|
Direct |
5,168
+26.2%
|
$268,736
$52.32 P/Share
|
|
Feb 07
2025
|
Alan J Malus |
BUY
Grant, award, or other acquisition
|
Direct |
4,040
+44.52%
|
$210,080
$52.32 P/Share
|
|
Feb 03
2025
|
Violetta Hughes VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
317
-3.2%
|
$16,484
$52.97 P/Share
|
|
Jan 31
2025
|
Ginger Zhou SVP and General Manager, Genom |
BUY
Open market or private purchase
|
Direct |
417
+1.47%
|
$18,765
$45.88 P/Share
|
|
Dec 05
2024
|
Lawrence Y. Lin EVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
28,813
+28.93%
|
$1,296,585
$45.0 P/Share
|
|
Dec 04
2024
|
David Dong Wang SVP & GM, SMS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
140
-0.58%
|
$6,440
$46.65 P/Share
|
|
Nov 19
2024
|
Herman Cueto EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
712
-2.89%
|
$28,480
$40.07 P/Share
|
|
Nov 19
2024
|
Jason Joseph SVP, General Counsel, Secy. |
SELL
Open market or private sale
|
Direct |
1,139
-1.0%
|
$45,560
$40.07 P/Share
|
|
Nov 19
2024
|
David Dong Wang SVP & GM, SMS |
SELL
Open market or private sale
|
Direct |
348
-1.42%
|
$13,920
$40.07 P/Share
|
|
Nov 19
2024
|
Ginger Zhou SVP and General Manager, Genom |
SELL
Open market or private sale
|
Direct |
491
-1.75%
|
$19,640
$40.07 P/Share
|
|
Nov 19
2024
|
Violetta Hughes VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
163
-1.62%
|
$6,520
$40.07 P/Share
|
|
Nov 19
2024
|
Olga Pirogova SVP and CHRO |
SELL
Open market or private sale
|
Direct |
548
-2.75%
|
$21,920
$40.07 P/Share
|
|
Nov 19
2024
|
John Marotta President and CEO |
BUY
Open market or private purchase
|
Direct |
1,250
+1.22%
|
$50,000
$40.67 P/Share
|
|
Nov 19
2024
|
Martin D Madaus |
BUY
Open market or private purchase
|
Direct |
4,940
+40.02%
|
$197,600
$40.77 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 238K shares |
|---|---|
| Sale (or disposition) back to the issuer | 995 shares |
| Open market or private purchase | 32.8K shares |
| Sale (or disposition) back to the issuer | 5.72K shares |
|---|---|
| Open market or private sale | 5.31K shares |